MétaCan
Menu
Back to cohort
Record W4396991660 · doi:10.1681/asn.20213210s1420d

Long-Term Efficacy of Migalastat on Renal Function and Outcomes in Patients with Fabry Disease (FD)

2021· article· en· W4396991660 on OpenAlexaff
Daniel G. Bichet, Ulla Feldt‐Rasmussen, Roberto Giugliani, Derralynn Hughes, Eva Krusinska, Biliana O. Veleva-Rotse

Bibliographic record

VenueJournal of the American Society of Nephrology · 2021
Typearticle
Languageen
FieldMedicine
TopicLysosomal Storage Disorders Research
Canadian institutionsUniversité de MontréalHôpital du Sacré-Cœur de Montréal
Fundersnot available
KeywordsFabry diseaseMedicineRenal functionUrologyTerm (time)Internal medicineDiseasePhysics

Abstract

fetched live from OpenAlex

Background: FD, caused by pathogenic GLA variants leading to functional deficiency of α-galactosidase A (α-Gal A), can eventually result in key organ damage. Preserving renal function and preventing Fabry-associated clinical events (FACEs) are important treatment goals. Approved therapies include enzyme replacement therapy (ERT) and the pharmacological chaperone migalastat. Stabilized renal function and FACE occurrence up to 30 mo have been reported in migalastat-treated adults with amenable GLA variants; here, we extend those analyses up to 8.6 yrs. Methods: Integrated data from phase 3 clinical trials (FACETS, NCT00925301; ATTRACT, NCT01218659) and open-label extension studies (NCT01458119; NCT02194985) were used to evaluate the eGFR slope using linear regression in pts treated with migalastat for ≥2 yrs (n=78). Incidences of FACEs (predefined renal, cardiac, and cerebrovascular events) were assessed in all pts (N=97). Analyses were stratified by prior treatment and phenotype. Cox regression modeling was used to identify predictors of FACEs. Results: eGFR remained stable for both ERT-naive and ERT-experienced pts who received migalastat for ≥2 yrs (median [min-max] duration: 5.9 [2.0-8.6]); the mean (SD) annualized rates of change in eGFR (mL/min/1.73 m2) were -1.6 (3.1) and -1.6 (3.6), respectively. In male pts with the classic phenotype (classification based on multiorgan involvement and [ERT-naive only] α-Gal A level at baseline; n=25), mean (SD) rate of change in eGFR was -2.2 (4.4) mL/min/1.73 m2. eGFR was also analyzed by baseline renal function and proteinuria levels. In all migalastat-treated pts (median duration: 5.1 yrs), the incidence of composite FACEs (per 1000 patient-years) was 48.3 (65.3 for classic males) and incidence of renal events was 4.4 (14.5 for classic males). Lower baseline eGFR was a predictor of FACEs in classic males vs all others; however, rate of renal events was too low to analyze predictors. Conclusions: Results demonstrate long-term efficacy of migalastat in stabilizing eGFR in pts with FD, including male pts with the classic phenotype. FACE incidence in pts receiving migalastat compared favorably to historic reports of ERT. The inverse correlation of eGFR with FACEs suggests the importance of early diagnosis and treatment to preserve renal function. Funding: Commercial Support - Amicus Therapeutics, Inc.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.282
Teacher spread0.270 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the American Society of NephrologySame topicLysosomal Storage Disorders ResearchFrench-language works237,207